Convalescent plasma for COVID-19: a meta-analysis, trial sequential analysis, and meta-regression.

ABSTRACT:

Background

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific antibodies, particularly those preventing interaction between the viral spike receptor-binding domain and the host angiotensin-converting enzyme 2 receptor, may prevent viral entry into host cells and disease progression.

Methods

We performed a systematic review, meta-analysis, trial sequential analysis (TSA), and meta-regression of RCTs to evaluate the benefit of convalescent plasma for COVID-19. The primary outcome was 28-30 day mortality. Secondary outcomes included need for mechanical ventilation and ICU admission. Data sources were PubMed, Embase, MedRxiv, and the Cochrane library on July 2, 2021.

Results

We identified 17 RCTs that recruited 15 587 patients with 8027 (51.5%) allocate

SUBMITTER: Snow TAC 

PROVIDER: S-EPMC8403663 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature